Louis Garguilo Articles
-
Creating T Cell Vaccines In The Sands
1/25/2024
Like others, Saudi Arabia has been dependent on vaccines supply from abroad. That’s about to change. According to the CEO of Emergex, the Saudis intend to produce a new generation of vaccines – predominantly based on "T cell priming, the next step beyond mRNA vaccines.”
-
Vaccine Manufacture From The U.K. to Brazil And Saudi Arabia
1/22/2024
Why is Professor Thomas Rademacher’s U.K-based vaccine-creating biotech so important that Saudi Arabia has based the establishment of the Kingdom’s first vaccine manufacturing facility on the company? The narrative starts in Brazil.
-
Reinventing The Classic Pharma Campus
1/15/2024
Perhaps your company is located on, or considering expanding to, a biopharma or life-sciences campus. Ever wonder how these “campuses” (or “parks”) materialize? Jason Benson of JLL Life Sciences Real Estate Solutions explains to chief editor Louis Garguilo.
-
Technical Talent Tailing Off At CDMOs?
1/11/2024
“Having been outsourcing to CDMOs for 20 years in the small-molecule space, I see a distinct difference in technical performance compared to my mid-2000s CDMOs," says an executive. What's going on here?
-
Development And Commercial: 2 Supply Chains For An Ideal Future
1/5/2024
How do you transition a supply chain utilized for your development stages to a robust commercial supply chain? Thierry Bilbault knows how. He does done it before, and is at it again. He shares his strategies and secrets.
-
2024: An Outsourcing Future of Information Sharing
1/3/2024
I'm a big believer in open-source information as much as possible,” says Nana Collett. “Companies need proprietary information, but I'm a bit radical this way. I believe that as an ecosystem, we're going to get stronger if we can find our way to more data-sharing.”
-
Oligonucleotides Outsourcing In 2024
12/26/2023
2023, among other potential designations, was the year of oligonucleotides. Accordingly, here’s a question I raised with professionals throughout the year: How do you successfully outsource development and manufacture of an oligo program?
-
Will 2024 Unlock Options Enabling Our Technologies
12/20/2023
Our Advisory Board members describe their outsourcing experiences during 2023, and offer us ideas and questions on how to make 2004 a better environment, specifically for all our advancing platforms.
-
How To ID The Best CDMOs
12/13/2023
It takes a certain, trained perspicuity to identify the CDMO right for you. If you are a small biotech, says CEO Matthias Schroff, you most likely will not have the weight to ensure an external partner’s “real focus on producing for you.” Here's what he recommends.
-
Switching From Car T To Car M Changed An Outsourcing Strategy
12/7/2023
A strategic switch in focus from a CAR T program closing in on the clinic, to a CAR M program further back in development but generating more excitement, drove the divesting of a manufacturing facility, and a whole lot of change. Part 2 of an investigative series.